A Study Evaluating Safety and Tolerability of Switching From Semaglutide to Zovaglutide in Adults With Obesity (HORIZON-SWITCH-SZ)

Prior treatment

• Previously diagnosed obesity caused by monogenic mutations, other diseases, or medications.
• Used of medicines or treatments that affect weight within 3 months prior to screening.

Other illness

• History of acute or chronic pancreatitis, or pancreatic injury.
• History of medullary thyroid carcinoma (MTC) or type 2 multiple endocrine neoplasia (MEN2) in personal or family history.
• History of medullary thyroid carcinoma (MTC) or type 2 multiple endocrine neoplasia (MEN2) in personal or family history.

Lab values

• Previous diagnosis of diabetes; or HbA1c ≥ 6.5% or fasting blood glucose ≥ 7.0 mmol/L at screening.

Other

• Patient Health Questionnaire-9 (PHQ-9) scale score is ≥ 15 at screening
• Screening Columbia-Suicide Severity Rating Scale(C-SSRS) questionnaire suicide ideation response of "Category 4 or 5," or any "yes" response to suicidal behavior questions

• Male or female subjects aged≥18years and≤75 years at the time of signing the Informed Consent Form (ICF).
• At screening, Body Mass Index (BMI)≥28kg/m²
• Weight change due to diet and exercise alone within 3 months prior to screening did not exceed 5%.